Table 2 |
||||||
|
Change in GFRe in response to FONT study intervention: Rosiglitazone versus adalimumab |
||||||
|
Patient # |
Rosiglitazone |
Adalimumab |
||||
|
|
||||||
|
Follow-up interval (months) |
ΔGFRe slope* |
Follow-up interval (months) |
ΔGFRe slope* |
|||
|
|
||||||
|
Pre |
Post |
Pre |
Post |
|||
|
|
||||||
|
1 |
12 |
21 |
7.91 |
6 |
10 |
-0.39 |
|
|
||||||
|
2 |
25 |
19 |
0.46 |
16 |
6 |
4.04 |
|
|
||||||
|
3 |
7 |
26 |
-5.73 |
14 |
18 |
-2.28 |
|
|
||||||
|
4 |
23 |
20 |
0.91 |
11 |
20 |
0.12 |
|
|
||||||
|
5 |
12 |
20 |
-4.01 |
50 |
17 |
6.35 |
|
|
||||||
|
6 |
12 |
9 |
1.96 |
6 |
17 |
10.36 |
|
|
||||||
|
7 |
14 |
17 |
6.42 |
23 |
16 |
0 |
|
|
||||||
|
8 |
12 |
13 |
4.23 |
18 |
16 |
1.33 |
|
|
||||||
|
9 |
24 |
25 |
3.58 |
32 |
7 |
0.62 |
|
|
||||||
|
10 |
25 |
20 |
-1.65 |
23 |
14 |
-11.69 |
|
|
||||||
|
11 |
20 |
7 |
3.23 |
|||
|
|
||||||
|
Mean ± SD |
16.8 ± 6.4 |
18.0 ± 6.0 |
1.72 ± 4.10 |
20 ± 13 |
14 ± 5 |
0.84 ± 5.78 |
|
|
||||||
|
*The change in slope is reported as ml/min/1.73 m2/month |
||||||
|
Peyser et al. BMC Nephrology 2010 11:2 doi:10.1186/1471-2369-11-2 |
||||||
